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Welcome!
Not long ago, the field of cancer immunology
and immunotherapy (ie: harnessing the patient’s
own immune system to fight cancer) was considered the “road to nowhere.” As an earlier member
of a generation of “dreamers” and “truly believers”
in this field, I was thrilled to learn this fall, that the
Nobel Foundation in Stockholm presented the 2018
Nobel Prize in Physiology or Medicine to two cancer immunotherapy pioneers, James P. Allison and
Tasuku Honjo, “for their discovery of cancer therapy
by inhibition of negative immune regulation.”
The rise to prominence for the rapidly expanding scientific field is also gratifying news for the
members of the George Washington University
(GW) Cancer Center, as cancer immunology and
immunotherapy research is a cornerstone of our
basic science efforts — along with cancer biology
(genetics, genomics, and epigenetics), microbial
oncology, and cancer engineering. Together with
our community outreach and engagement initiatives, cancer control, prevention and policy efforts
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and education, we are committed to rapidly move
these areas of discovery to benefit the community
we serve in Washington, D.C., and the surrounding
counties.
At the GW Cancer Center, we have many investigative teams pursuing immunological research to
refine and develop this new generation of cancer
therapies. By tapping into the body’s immune system to fight disease, we are “re:discovering” that
the cure is inside us. Although cancer immunotherapy has been around for several decades, and after
many failures, basic and translational investigations
have begun to yield revolutionary results.
Featured in this edition of re:discover is work
by Catherine Bollard, MD, who has developed a
new immunotherapy called TAA-T, which is a multiantigen specific T-cell product that appears to be
superior in many ways and with less toxicity that the
recently FDA-approved CAR T-cell therapy. Another team of GW Cancer Center investigators, led by
Rohan Fernandes, PhD, is integrating nanotechnology with the immune response to achieve greater
therapeutic results. They have re:discovered a use
for nanoparticles found in a pigment once commonly used by the world’s great artists. Those tiny
particles are super-heated to destroy previously
inaccessible tumor tissue in the brain. And a third
research team, led by Katherine Chiappinelli, PhD,
is pouring through the body’s “junk DNA” to define
the mechanisms controlling the immune signaling
in cancer cells. By understanding how to increase
the immune signaling coming from tumors, we can
increase the number of immune cells in the tumors
and make immunotherapies even more effective.
This basic and translational science research is
a key facet of our comprehensive approach to cancer care. Projects such as these help to inform our
clinical research enterprise, and those programs
help to advance cancer care at every level. Reading
these and other stories in the pages of re:discover,
I hope you’ll agree that the new generation of scientific “dreamers” and innovators we have brought
together under the umbrella of GW Cancer Center are well-poised to transform cancer care and,
hopefully one of them will receive a phone call from
Stockholm one cold morning in October.

EDUARDO SOTOMAYOR, MD
Director, George Washington
University Cancer Center
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IN BRIEF

Genetic Junk Is Too Good to Throw Away
Less than 3 percent of the DNA
in our genome encodes proteins.
Recent work has shown that a significant part of the genome, initially considered “junk DNA,” does not code
for proteins, but still has important
biological functions, especially in
cancer initiation and progression. A
two-year, $300,000 grant from the G.
Harold and Leila Y. Mathers Foundation will help fund research led by
Katherine Chiappinelli, PhD, assistant
professor of microbiology, immunology, and tropical medicine at SMHS,
to define epigenetic determinants of
repetitive element “junk DNA” control during tumor progression and
lay the groundwork for understanding interactions between these elements and the host immune system.
The research project, titled “Epigenetic Modification and Expression

of Retroelements in Cancer Development,” includes a subcontract with
Kathleen Helen Burns, MD, PhD, at
Johns Hopkins Medicine, an expert
in the field of repetitive elements in
cancer. Repetitive elements are very
different in cancer cells than they
are in normal cells, but the medical
community does not yet know which
elements are affected and how they
are altered as the cancer progresses.
Outcomes of the project will include
a more complete understanding of
cancer progression and the identification of novel cancer therapeutic
targets and/or biomarkers.
Chiappinelli and her colleagues
will work to produce a comprehensive map of repetitive element
regulation and expression during
the progression of common tumors,
including lung and ovarian cancer.

A Vision for
Public Health
Lorien
Abroms, ScD,
associate
professor
of prevention
and community health
at the Milken
Institute
School of Public Health at GW, has been named
interim associate center director for
population sciences and policy at the
GW Cancer Center.
In this role, Abroms collaborates
with faculty across GW to create a
vision for the public health programs
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within the GW Cancer Center. She
develops and manages initiatives
to foster university-wide cancer research collaborations among population sciences and policy researchers.
Abroms is a behavioral scientist
with expertise in applying communication technology to design scalable
programs aimed at tobacco cessation. Her responsibilities also include
identifying and nurturing the development of program areas in cancer
population sciences and policy, such
as screening, environmental carcinogens, health care disparities, cancer
epidemiology, and virus-related
cancers such as HIV and HPV.

Survivorship
e-Learning Series
The George Washington University (GW) Cancer Center
offers The Cancer Survivorship ELearning Series for Primary Care
Providers (E-Learning Series), a
free, self-paced continuing education program for primary care
providers interested in learning
more about the needs of posttreatment cancer survivors.
The module-based, online
format prepares physicians to
care for, and attend to, the needs
of cancer survivors by providing
cancer specific guidelines for
colorectal, breast, head and neck,
and prostate cancer survivors. The
e-learning series offers access to
the latest practice-based insights
and experiences from cancer
survivors. The self-paced modules
typically take an hour, but they can
be completed in as many sittings
as necessary, enabling health care
providers to earn continuing education credits at their own pace.
The E-Learning Series is a
program of the National Cancer
Survivorship Resource Center, a
collaboration between the American Cancer Society and the GW
Cancer Center funded through a
five-year cooperative agreement
with the Centers for Disease Control and Prevention.
For more information or to
enroll in the training, visit
cancercenter.gwu.edu/forhealth-professionals.

IN BRIEF

Building a Bigger BMT Presence
The George Washington University (GW) Cancer Center has
assembled an internationally recognized team of experts to bring
innovative and cutting-edge cellbased therapy options to patients in
the Washington, D.C., area.
John Barrett, MD, professor of
medicine at the GW School of Medicine and Health Sciences, heads up
the bone marrow transplant and cell
therapies (BMT) expansion at the
GW Cancer Center, including the
translation of clinical research efforts
into novel immune cell treatments.
Barrett previously served as chief
of the Stem Cell Transplantation
Section of the hematology branch of
the National Heart, Lung, and Blood
Institute, where he began the stem
cell transplant program.
“Dr. Barrett is known and respected throughout the international
transplant and hematology communities for his contributions as a
physician-scientist,” said Mitchell
Smith, MD, PhD, associate center director for clinical investigations and
director of the Division of Cancer and
Blood Disorders at the GW Cancer
Center. “We know he will help us

accomplish great things here at the
GW Cancer Center, and are thrilled to
have him join our leadership team.”
Barrett joins Catherine Bollard,
MD, a pioneer and internationally
recognized leader in the field of immune cell therapies — in particular,
novel T-cell based treatments for
pediatric and adult patients with
hematologic malignancies. Bollard,
associate center director for translational research and innovation at the
GW Cancer Center, also serves as
the director of the Center for Cancer
and Immunology Research at the
Children’s Research Institute and is a
member of the Division of Blood and
Marrow Transplantation at Children’s
National Health System.
When Eduardo M. Sotomayor,
MD, director of the GW Cancer
Center and professor of medicine,
joined the GW School of Medicine
and Health Sciences in 2015, it didn’t
take long for him to pick Bollard out
from the crowd. “I realized then that
together with Dr. Bollard, we would
be able to build a world-class program in immune cell-based therapies … which is happening now,”
said Sotomayor. Bollard, he added,

played a key role in the recruitment
of Eric Yvon, PhD, who came to GW
from MD Anderson Cancer Center to
direct the newly established cGMP
Cellular Production Facility at the
GW Cancer Center.
“Dr. Yvon is one of the few experts
in the nation capable of engineering
or genetically modifying any type of
immune cell,” said Bollard. “To build
a premier cell therapy research and
translational program, we recognized that we needed to recruit one
of the best.”

Lead Role in Radiation Research
Sharad Goyal, MD, professor of radiology at the George Washington University (GW) School of Medicine and Health
Sciences, was recently selected as a member of the NRG Oncology Developmental Therapeutics Radiation Therapy
Subcommittee, where he will spend the next two years collaborating with fellow committee members and the National Institutes of Health to bring new drugs to clinical trials.
“I think this is a great opportunity to give GW a place at the table with respect to working in a cooperative group,”
said Goyal. “It raises the profile of not only radiation oncology, but also GW and the GW Cancer Center.”
NRG Oncology is one of three major cooperative groups that run clinical trials across the United States. There are subcommittees that cover each type of cancer that NRG Oncology works on. The Developmental Therapeutics Radiation Therapy Subcommittee helps to determine what molecular pathways or drug combinations may be more interesting or feasible
in treatments. It also determines what types of tumors may benefit from those drug combinations with radiation therapy.

The George Washington University Cancer Center
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Robert Siegel Presents Study on
Oropharyngeal Cancer at ASCO

ELIMINATING THE
NEED FOR RADIATION
Robert Siegel, MD ’77, described
a new treatment developed for
patients suffering from oropharyngeal cancer during the American Society of Clinical Oncology’s
Annual Meeting, held in Chicago.
The investigational treatment,
based on findings from a Phase
II study, eliminates the need
for radiation in most patients.

In June 2018, before a room full of
oncology experts, Robert Siegel, MD
’77, described a new treatment developed for patients suffering from
oropharyngeal cancer.
Siegel, associate center director
for education, training, and network
development at the George Washington University (GW) Cancer Center, presented findings from a Phase
II study during the American Society
of Clinical Oncology’s (ASCO) Annual
Meeting, held in Chicago.
Oropharyngeal cancer involves
the base of the tongue, floor of the
mouth, and tonsils, said Siegel. It’s
not the most common cancer, but is
also not a rare one, he noted.
“Historically, patients who develop this cancer have smoked heavily
and consumed large amounts of
alcohol,” he said. However, now most
oropharyngeal tumors are a consequence of human papillomavirus
(HPV) infection; patients with HPV
often have no history of heavy smoking or alcohol abuse. HPV tumors are
more responsive to both chemotherapy and radiation, he added.
The current standard treatment
includes a combination of high-dose
radiation plus chemotherapy. Siegel
noted that the treatment is “80 to 90
percent successful.” However, the
radiation leaves patients suffering
from myriad side effects.
Short-term effects include damage to the back of the throat that
makes eating painful, and often creates the need for gastrostomy tubes

Today, most oropharyngeal tumors are a
consequence of human papillomavirus infection.
4
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to maintain adequate nutrition. In
the long term, radiation knocks out
the salivary glands, leaving patients
with chronic dry mouth, which can
lead to increased gum and dental
disease. The radiation can also alter
a patient’s sense of taste and cause
chronic swallowing problems.
The investigational treatment eliminates the need for radiation in most
patients. Instead, said Siegel, patients
receive three doses of standard chemotherapy followed by surgery.
“We found that the primary cancer
and involved lymph nodes shrank
dramatically with chemotherapy,” he
said. After chemotherapy treatment,
the cancer was removed through
a new technique — TORS (transoral
robotic surgery). Siegel credited
Nader Sadeghi, MD, a former faculty
member, for bringing the technique
to GW. Currently that technology
is used by GW School of Medicine
and Health Sciences head and neck
surgeons Arjun Joshi, MD, associate
professor of surgery; Punam Thakkar,
MD, assistant professor of surgery;
and Joseph Goodman, MD, assistant
professor of surgery.
Siegel added that throughout
the study, patients were referred to
standard radiation therapy if the new
treatment wasn’t working. “We were
doing something unique, and we
wanted to make it as safe as possible
for the patients,” he said.
Sixteen of the 20 patients in the
study never needed radiation, and
18 of 20 patients remain in remission.
“We saw at least equal effectiveness
in the treatment, but were cutting way
back on the side effects,” Siegel said.
Siegel would like to add two more
steps in a follow-up study: using nextgeneration sequencing of the tumor
to identify which patients are at high
risk for relapse, and incorporating additional drugs, such as immunotherapy drugs, to see if they would make
the treatment even more effective.

IN BRIEF

GENE CONNECTED TO
PANCREATIC CANCER UNCOVERED
Alexandros Tzatsos, MD, PhD, (on right)
has uncovered a connection between a
specific gene, KDM6A, and the most aggressive form of pancreatic cancer.

X Marks the Spot on Pancreatic Cancer
Alexandros Tzatsos, MD, PhD,
assistant professor of anatomy and
cell biology at the George Washington University (GW) School of
Medicine and Health Sciences and a
researcher at the GW Cancer Center,
has uncovered a connection between a specific gene, KDM6A, and

the most aggressive form of pancreatic cancer.
Tzatsos’ study, published in Cancer
Cell, found that a loss of KDM6A, an
X chromosome-encoded histone
demethylase, induces a histologically
distinct subtype of pancreatic cancer
known as “squamous-like.” The gene,

Tzatsos and his team found, is also
frequently mutated or deleted in
squamous-like pancreatic cancer and
acts as a tumor suppressor. He further determined that bromodomain
and extra-terminal inhibitors, a class
of small molecules now in clinical trials for treating several malignancies,
could offer a potential treatment by
restoring cell identity and sensitizing
tumors to current therapies.
Pancreatic cancer accounts for
3 percent of cancers in the United
States, and 7 percent of all cancer
deaths. The squamous-like subtype
of this cancer offers the worst prognosis and accounts for 20–30 percent
of pancreatic cancer cases.

Lung Cancer Screening Excellence at GW
The George Washington University Hospital, along with the GW Cancer Center, recently earned a Screening
Center of Excellence designation from the Lung Cancer Alliance (LCA) for its ongoing commitment to responsible
lung cancer screening. GW Hospital is one of only two hospitals in the region to hold this distinction.
“GW Hospital and the GW Cancer Center are committed to bringing lifesaving cancer research, screenings, and
treatment to [the] community,” said Kimberly Russo, MBA, MS, chief executive officer and managing director at GW
Hospital, adding that low-dose CT screening for lung cancer — carried out safely, efficiently, and equitably — saves tens
of thousands of lives a year. “We are proud to receive this recognition that reflects this ongoing and focused dedication to reducing cancer deaths across our region.”
GW Hospital has been performing low-dose CT screenings for lung cancer for four years. In that time, the hospital
has performed more than 800 screenings and identified 320 at-risk individuals. The scan itself takes only 60 seconds
to complete and is covered by Medicare and most insurance plans.
“Early detection of lung cancer in high-risk individuals is vital to effective treatment,” said Keith Mortman, MD, associate professor of surgery at the GW School of Medicine and Health Sciences and chief of the Division of Thoracic
Surgery at GW Hospital. “By finding lung cancer early, we are able to work closely with our patients and multidisciplinary teams to create a care plan that will yield the best possible outcomes.”
Individuals may be at high risk if they meet the following criteria: they are between 55 and 77 years old; have
smoked a pack of cigarettes or more every day for at least 30 years; and are a current smoker, or quit smoking less than
15 years ago. It is recommended that those people have a baseline CT scan with annual follow-up scans. To schedule
an appointment, call 1-855-495-8647 (1-855-GWLUNGS).

The George Washington University Cancer Center
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GW-SPARC Fuels
Passion for Research
BY KATHERINE DVORAK

Lexis Deshazor-Burnett, a rising junior at North Carolina A&T

“GW-SPARC not only
exposes participants to
cutting-edge research
and contemporary cancer
research techniques, but also
fosters their understanding
of health disparities and
the impact of cancer in
different communities.”
ALISON HALL, PhD
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State University, credits the George Washington University (GW)
Summer Program Advancing Research on Cancer (GW-SPARC) with
opening her eyes to the myriad research paths she could follow.
Becoming a doctor was always her goal, she said, but once arriving at college, Deshazor-Burnett discovered a new passion: research.
Through GW-SPARC, she spent the summer in the lab of Alexandros Tzatsos, MD, PhD, assistant professor of anatomy and cell biology at the GW School of Medicine and Health Sciences (SMHS) and
researcher at the GW Cancer Center. She assisted with using CRISPR,
a revolutionary gene editing tool, to knockout KDM6A, a histone demethylase, in pancreatic cancer cell lines.
“I’m thinking about what I want to do, and it was great to see a lot of
different types of people [at SMHS] with a lot of different careers,” she
said. “It gave me a broader idea of what I could do after undergrad,
and how I can satisfy each facet of what I want to do in my career.”
New to GW this year, the program is open to undergraduate school
students from groups underrepresented in biomedical science and
provides participants with a hands-on approach to cancer research.
Students worked in laboratories focused on cancer immunology and
immunotherapy; cancer biology, namely targeted therapies and epigenetics; and cancer engineering and technology.
The goals of GW-SPARC, according to Alison Hall, PhD, associate
dean for research workforce development and professor of neurology at SMHS, who serves as co-director of the program, are to expand
opportunities for potential researchers and enhance diversity in the
biomedical research community.
“GW-SPARC not only exposes participants to cutting-edge research and contemporary cancer research techniques, but also fosters their understanding of health disparities and the impact of cancer
in different communities,” said Hall.
Students attended workshops on topics including sample size and
experimental design, applying to graduate and medical school, and
how to make a research poster. They also sat in on seminars from GW

Cancer Center researchers, such as Katherine Chiappinelli, PhD, assistant professor of microbiology, immunology, and tropical medicine
at SMHS; Norman Lee, PhD, professor of pharmacology and physiology at SMHS; and Edward Seto, PhD, associate center director for
basic sciences at the GW Cancer Center, King Fahd Professor of Cancer Biology, and professor of biochemistry and molecular medicine at
SMHS, who is also a co-director of GW-SPARC.
Ann Obi, a rising junior at Prairie View A&M University, worked in
Chiappinelli’s lab over the summer. She first was drawn to medicine
after visiting family in Nigeria during a summer break in high school
and realizing the lack of health care services available there.
Obi said working in Chiappinelli’s lab was an exceptional experience.
“Everyone is nice and understanding. I don’t have a strong research
background, so they really made an effort to make sure I understood
what was going on. Dr. Chiappinelli was very open to answering all my
questions,” she said. “I learned a lot.”
In addition to their time in the lab, cohort members also were required to create a poster on their research and presented their findings to faculty and staff on the last day of the program.
Obi confidently presented her research to the crowd gathered in
the Science and Engineering Hall that day, answering questions with
a confident smile.
Before the presentation began, Hall and Seto said a few words to
the students and attendees.
“This past week I had a chance to talk to the students, and I asked
them what they liked about the program, and a lot of them told me ...
they were surprised that the faculty here, despite their busy schedules, were willing to sit down with them to talk with them and talk
about their passion and how they got into science,” Seto remarked.
“To the students, I want to say this is a mutual feeling. As a faculty
member, I’ve learned a lot from you and benefited from the enthusiasm you’ve brought to this program.”
The GW Hospital Women’s Board provided partial support for
this initiative.

A PASSION FOR RESEARCH
Becoming a doctor was always
Lexis Deshazor-Burnett’s goal, but
once at college, she developed a
passion for research. The George
Washington University Summer
Program Advancing Research on
Cancer and her work in the lab
of Alexandros Tzatsos, MD, PhD,
opened her eyes to the myriad
research paths she could follow.

The George Washington University Cancer Center
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HARNESSING THE POWER OF

THE IMMUNE SYSTEM
BY KATHERINE DVORAK

The future of cancer research, in the opinion of Katherine Chiappinelli, PhD, of the
George Washington University School of Medicine and Health Sciences (SMHS), revolves
around combining immunotherapy with other treatments. Pairing immunology with epigenetics, the study of changes in organisms caused by modifications to gene expression,
she seeks to better understand the mechanisms behind epigenetic control of immune
signaling in cancer cells.
“The body’s own immune system is our most potent weapon against cancer cells,”
says Chiappinelli, assistant professor of microbiology, immunology, and tropical medicine at SMHS.
Although immunotherapy alone can work to fight cancer, Chiappinelli notes, it is most
successful in patients who already have immune cells in their tumors. “Those patients in
general respond to immune therapy, but there’s another set of patients [whose] tumor
cells are growing very fast and there are few or no immune cells in the tumor to fight it,”
she says. “These patients don’t do well with drugs that release the brakes on the host immune system. That’s a big problem in the field.”
And it’s a problem her lab is tackling head-on.
During a postdoctoral fellowship with Stephen Baylin, MD, at Johns Hopkins University, Chiappinelli found that a drug that activates tumor suppressor genes also has a strong
immune effect.
“When we treated cancer cells with this drug, they had more immune signaling coming
from the tumors and more immune cells in the tumors. But we didn’t know why,” she says.
It turned out the answer was in our genomes. “Only about 2–3 percent of [human] DNA
codes for proteins. However, about half of our DNA is repetitive sequences, and we don’t
really know what they do,” she says. Originally, that was characterized as junk DNA, but it’s
not junk, according to Chiappinelli. Those sequences include endogenous retroviruses,
or dead viruses in our genetic code. Our cells turn off these viruses on purpose. But epigenetic drugs turn them back on.
We don’t get viral particles that can infect the cell when the retroviruses get a green
light, Chiappinelli explains, but the viral RNA is transcribed, and that sets off an alert in
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By pairing immunology
with epigenetics,
Katherine Chiappinelli,
PhD, seeks to better
understand the
mechanisms behind
epigenetic control of
immune signaling
in cancer cells.

the cell. “The alert makes tumor cells think they are infected
OUR BEST DEFENSE
Katherine Chiappinelli, PhD, says
with a virus, and they die or send out signals to host immune
the body’s own immune system
cells to come and kill them,” Chiappinelli says. “So the big efis our most potent weapon
fect in human cancer cells and in mouse models of cancer is
against cancer cells. Although
that you get more immune cells coming in to kill the tumor
immunotherapy alone can work
and a good anti-tumor effect, especially when you combine
to fight cancer, Chiappinelli
that with immune therapies.”
notes, it is most successful in
Chiappinelli’s interest in medical research dates back to
patients who already have
high school AP biology. It was a hands-on class full of lab work
immune cells in their tumors.
that showed her how pursuing science could mean doing
something different every day and enjoying the excitement of
not knowing what would happen next.
“That can be frustrating sometimes,” she says about the unknowns of scientific research, “but I think it also makes for a really interesting career.”
She notes that she gravitated toward epigenetics, a new field during her time in graduate school, because not much was known about it then, and researchers still have much
to learn.
“I think, for a young person, there’s the opportunity to make important discoveries.
It’s a field where there’s still a lot of progress to be made, in terms of both basic science
discoveries and impact on patient care,” she adds.
Now a clinical trial Chiappinelli was involved in during her postdoctoral work at Johns
Hopkins is underway, combining epigenetics with immune therapy. But even with the
discoveries she’s helped make, Chiappinelli has more questions to answer: Which sequences do this? What things are being secreted to bring in the host immune cells? What
are the best combinations to fully eradicate tumors?
That’s what Chiappinelli says she likes most about her work, day in and day out: “There’s
always something new to discover.”
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Alumni Gift Supports Immunologic
and Epigenetic Research
Establishing the Marlene and Michael
Berman Endowed Fund for Ovarian Cancer
Research was both personal and professional
for Michael Berman, MD ’67, RESD ’69, a specialist in gynecologic oncology at the University of California, Irvine, Medical Center.
On a warm September day in 2017, Berman
toured the George Washington University
(GW) Cancer Center as part of Reunion Weekend at the GW School of Medicine and Health
Sciences (SMHS); it was on that tour that he met
Katherine Chiappinelli, PhD, assistant professor of microbiology, immunology, and tropical
medicine at SMHS, and spoke with her about
her research on immunology and epigenetics.
Berman, always interested in discoveries
that could benefit the patient population he
has been serving for nearly 50 years, was intrigued; not long after talking with the young
researcher, he wrote a $100,000 check to help
with the growth of the Chiappinelli Lab.
“We’re on the threshold for major advances
in immunology and immunological treatments
of cancers, and Dr. Chiappinelli’s research is the
kind that will lead to positive developments in
the care of patients with ovarian cancer,” he says.
That was the professional reason for Berman’s generous donation. His personal reason
hit closer to home; Berman’s wife, Marlene, who
passed away in 2014, had breast cancer. Later,
all four of his daughters tested positive for the
BRCA gene, which places them at a higher risk
for developing breast or ovarian cancers.
“It’s a strange set of events, when you think
about it,” Berman says. “I’m an oncologist with all
four daughters at risk for cancer. But I think we’re
not too far away from some major breakthroughs
that may help patients suffering from this devastating disease.” He adds that the donation was
also made to show his appreciation for his alma
mater, to which he feels greatly indebted.
“GW has permitted me and many others to
have an impact on the lives of the people who
trust us to make correct decisions and do the
right things for them,” he says. “It’s that indebtedness that made me want to give back.”

The George Washington University Cancer Center
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Counting on Clinical Trials
BY KATHERINE DVORAK
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Innumerable questions and concerns loom after a cancer diagnosis. Among
them: Should I participate in a clinical trial, or should I stick with the standard of care?
Cancer treatment success rates continue to rise. The National Cancer Institute
predicts that by 2024, almost 19 million people will live well beyond their diagnosis.
Clinical trials play an important role in such progress.
“[They] are the mechanism by which we make progress in the treatment of cancer,”
says Robert Siegel, MD ‘77, associate center director for education, training, and network development at the George Washington University (GW) Cancer Center and
professor of medicine at the GW School of Medicine and Health Sciences (SMHS).
Treatments and techniques from clinical trials may be more effective than the
current standard of care, or they may be equally effective but have fewer side effects, he explains.

Finding the right fit

A BETTER OUTLOOK
Cancer treatment success rates
continue to rise. Clinical trials
play an important role in that
progress, as treatments and
techniques from clinical trials
may be more effective than
the current standard of care, or
they may be equally effective
but have fewer side effects.

Not every patient who signs up to be a part of a clinical trial will be accepted. Trials
have certain criteria that a patient must meet to be included, measures that vary
from trial to trial.
A patient signing up to take part in a trial must first undergo a screening procedure, which can include blood tests, physical examinations, a CAT scan, an electrocardiogram (EKG) test, and other tests and procedures required for the study.
If patients have, say, an abnormal EKG, or if their medical record shows a history
of cardiovascular disease, they may be excluded from a trial. In addition, a person
who is confined to a bed may not be considered for participation.
Patients should be guided by their physician when considering participating in a
trial, Siegel says. Physicians can identify the right clinical trials for their patients and
determine whether they’re good candidates for participation.

The George Washington University Cancer Center
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A patient signing up to take part in a trial must first undergo a
screening procedure, which can include blood tests, physical
examinations, a CAT scan, an electrocardiogram test, and
other tests and procedures required for the study.

Before a patient is accepted for clinical trial,
he or she must review and sign an informed consent form. The form includes in-depth details on
the trial, such as participation requirements, possible side effects of the treatment, and possible
benefits.
Once the form is signed and the patient meets
all the eligibility criteria, therapy begins.

Participation expectations
Clinical trial volunteers will have to meet certain
obligations during the course of the trial. Some
of the obligations may depend on what stage of
development the drug is in.
“There will be questions that need to be answered about how the drug behaves in the patient, what sort of side effects it has, and how
quickly those [side effects] occur and disappear,”
explains Richard Lush, PhD, director of the Clinical Trials Office at the GW Cancer Center. “When
those questions need to be answered earlier in
the development, the patient might be asked to
come back into the clinic for additional visits so
that the patient can be checked and have laboratory tests done to make sure [he or she is] OK.”
In later development stages, visits may ease
up because doctors have a better understanding
of what to expect from the drug.
However, generally there is a limit to the number of visits a patient needs to make. “We realize
that people have lives they want to live even while
on a study,” Lush says.
He adds that patients are encouraged to talk
with the doctor and study team at any time if they
have questions, or if they are experiencing a new
symptom or side effect.
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Betting on benefits, but considering the risks
The benefits of a clinical trial can differ, as can any
associated risks.
The major benefit from a Phase I trial can be,
simply, a new option when other treatments have
been exhausted. Drugs administered during such
trials could prolong a participant’s life or better
their quality of life, says Imad Tabbara, MD, director of the GW Medical Faculty Associates Blood
and Bone Marrow Transplant Program and professor of medicine at SMHS. For Phase III trials, benefits could include a drug with improved efficacy,
treatment that is less toxic than the alternatives, a
medication that’s easier to administer, or a medication that causes milder or fewer side effects.
However, no trial is risk-free.
“We have to be frank and tell [patients] we
don’t know everything about this medication,
that’s why we’re doing this [closely regulated]
clinical trial,” Tabbara explains. “Sometimes unexpected things happen.”
He adds that if a patient experiences unexpected outcomes, the trial will be halted for further investigation into the problem. If a trial is
halted, patients experiencing positive outcomes
from the medication may be allowed to continue
to receive treatment, but that’s at the discretion
of the FDA, Tabbara says.

Post-trial
A trial that gets through to Phase III often results
in the treatment earning FDA approval and becoming a new option of care for patients across
the United States.
The decision to participate in a trial, and
whether it is the best option for an individual’s
wants, needs, and health, is completely in the patient’s hands.
But one thing is true: When patients participate and treatments are found to be effective, the
impact reverberates far beyond the clinic’s walls.
“For the benefit of all current and future patients with cancer, we need patients to volunteer
in trials so that we can advance the drugs that will
improve the lives of patients,” Lush says.

The Phases
Imad Tabbara, MD, director of the GW Medical Faculty Associates Blood and Bone
Marrow Transplant Program, and Richard Lush, PhD, director of the Clinical Trials
Office at the GW Cancer Center, offer their expertise and advice for understanding the steps of the clinical trial process.
Phase I: The first phase of a clinical trial allows researchers to determine the efficacy of a new treatment. Phase I trials also help determine the right dose of the
drug, demonstrate whether it has adverse side effects, and reveal any toxicity it
might have.
The patients, says Tabbara, “have received regular treatment, or standard treatment as we call it, and they didn’t respond to it, or they responded and then the
cancer progressed. Those are usually the best candidates,” he explains.
Phase II: These trials are the second phase of drug development. A trial reaches
Phase II once researchers have determined the effectiveness of the treatment. This
second step establishes the response of individual agents when treating specific
cancer types.
These trials are often randomized, meaning trial participants receive either the
new drug or a standard drug already in use. This enables researchers to compare
the efficacy of the new drug to other treatments.
Phase III: Larger randomized studies are engineered during a Phase III trial, which
frequently is conducted by more than one institution.
Phase III trials are conducted if the treatment demonstrated sufficient activity
in early stages of development. These trials are the last stage of testing prior to
submitting the drug for FDA approval.
Questions to Consider
From a patient perspective, before joining a clinical trial, the most important thing
is to get all the facts, speak with physicians, and ask, “is this what’s best for me?”
Valuable questions to consider include:
>> What are the potential side effects, and can they be managed easily?
>> What kinds of results have been established with this new treatment, for instance from Phase I or Phase II trials?
>> How much of a commitment will participating involve?
>> Have there been any unexpected reactions in patients already participating?
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UNDER ATTACK
A scanning electron micrograph of T-cells (blue) attacking
a lymphoma cancer cell (pink).
Chimeric antigen receptor
(CAR) T-cell therapy takes T-cells
from a patient’s bloodstream
and reprograms them to
recognize a specific protein
found on lymphoma cells. The
T-cells are reintroduced in the
patient where the find and
attack the lymphoma cells.
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An Inside Job
IMMUNOTHERAPY LOOKS TO HARNESS THE BODY’S
DEFENSE AND CURE CANCER FROM THE INSIDE OUT
BY STEVE GOLDSTEIN

As little as two decades ago early adopters of immunotherapy, looking to harness the body’s immune system to fight disease, toiled in the shadow of the holy trinity of cancer therapy — surgery, chemotherapy, and radiation therapy. Now, the immunological approach to cancer treatment has undergone a research renaissance. Times certainly have changed.
Following news of remarkable recoveries, this once-overlooked avenue to a cure for cancer has captured the public’s
imagination. Oncologists have embraced immunotherapy as
an important advancement, and the focus now is on refining
those therapies to increase the cure rate and ameliorate potential adverse side effects.
One of the most exciting developments on the immunological front is T-cell therapies for lymphoma. T-cells are a type
of lymphocyte produced or processed by the thymus gland
(the T comes from thymus) that actively participate in the immune response. Typically, the most widely reported among
these new treatments is CD19 CAR T-cell therapy. Doctors attach chimeric antigen receptors (CAR) to T-cells and reintroduce them in the patient to seek out cancer cells and produce
chemical compounds that destroy them.
A research team led by Catherine Bollard, MD, associate
center director for translational research and innovation at
A LEADER IN IMMUNOTHERAPY
the George Washington University (GW) Cancer Center, has
Catherine Bollard, MD, is the assocideveloped a different therapeutic approach called TAA-T,
ate center director for translational
which is a multi-antigen specific T-cell product that may be suresearch and innovation at the George
perior in many ways to the recently FDA-approved CD19 CAR
Washington University Cancer Center.
T-cell therapy.
“If you’ve got a tumor cell, there are several ways to kill it,” says Bollard, who also serves as professor of pediatrics at the GW School of Medicine and Health Sciences (SMHS) and director of the Center
for Cancer and Immunology Research at Children’s Research Institute, part of Children’s National
Health System (Children’s National). The CD19 CAR T-cell technique, she explains, involves genetically engineering a T-cell — adding an artificial receptor — so that it recognizes and kills the tumor.

The George Washington University Cancer Center

17

TAA-T requires no genetic engineering. Tumor-killing T-cells, present naturally in everyone,
are harvested from the patient and fed with cytokines or other chemicals in the lab where technicians grow their numbers to millions. They are
then re-infused into the patient. Bollard says the
entire process used to take three to six months,
which dimmed its luster. Now it can be completed in less than two weeks, “so it’s a much more
nimble process,” she notes.
Genetic modification, on the other hand, is
expensive and heavily regulated and thus a cumbersome process. TAA-T has none of these disadvantages. Moreover, CAR T is limited to recognizing proteins on the surface of the tumor cells, and
that is very restricting, Bollard explains. “There
are only a limited number of proteins on the surface of tumors (or ‘extracellular antigens’) you can
target with CAR T,” she says, “whereas our TAA-T
can target what is known as intracellular antigens
— proteins within the tumor cells — and there are
many more of these cancer-specific proteins that
can be targeted. In addition, because CAR T targets only one antigen, the patient can develop a
resistance to the therapy.”
The minimal toxicity of TAA-T is perhaps its most
significant advantage. Patients undergoing CD19
CAR T-cell therapy sometimes experience cytokine release syndrome, or CRS, which is caused
by a large, rapid release of cytokines and cellular
by-products into the bloodstream when the cancer cells are destroyed. Symptoms can vary from
the relatively mild — fever, nausea, headache, rash,
rapid heartbeat, low blood pressure, and trouble
breathing — to the more severe. According to Bollard, CD19 CAR T-cell therapy is associated with
“appreciable toxicities including neurotoxicity and,
in some cases, death.”

In Phase I clinical trials
A STRONG TEAM
Catherine Bollard,
with Bollard’s TAA-T therapy,
MD, (center), leads a
researchers are now seeing
team of internationally
75 percent efficacy, esperenowned researchers
cially in acute myeloid leuthe GW Cancer Center.
kemia, which the trials with
CAR T have thus far been unable to achieve. “We’re just beginning to increase
the number of patients [in the trials], both adult
and pediatric,” says Bollard. “We were initially collaborating with [Johns] Hopkins because the program at GW wasn’t up and running, but with Kieron’s arrival at GW we are now ready to move this
therapy forward at GW for the treatment of other
forms of lymphoma and even multiple myeloma.”
Kieron is Kieron Dunleavy, MD, director of the
lymphoma program and professor of medicine
at SMHS. “We are excited for Kieron to lead the
novel T-cell therapy studies at GW,” Bollard says.
“We obviously see GW as a huge player in this
because of Eduardo [Sotomayor, MD, director of
the GW Cancer Center and professor of medicine
at SMHS], Kieron, and Mitch [Smith, MD, PhD, associate center director for clinical investigations
at GW Cancer Center], who are all internationally
renowned lymphoma physicians.”

Chimeric Antigen Receptor (CAR) T-cell Therapy
The concept of engineering chimeric antigen receptors dates back about 20 years, and it has
been touted as a treatment for a range of cancers. Two CAR T-cell therapies were approved by the
FDA in 2017, and since then the number of immunotherapy trials has grown.
Cytokine Release Syndrome, or CRS, occurs after CAR T-cell treatment. Symptoms such as fever,
nausea, headache, or trouble breathing can range from mild to severe or even life-threatening. According to the National Cancer Institute, the more effective the CAR T-cell treatment is, the more
likely a patient is to experience CRS because the therapy has destroyed so many cancer cells the
body is littered with cellular debris. The rapid release of cytokines into the blood from the immunotherapy can send the immune system into a tailspin.
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A research team led by Catherine Bollard, MD,
has developed a therapeutic approach called
TAA-T, which may be superior in many ways to the
recently FDA-approved CD19 CAR T-cell therapy.
Dunleavy came to GW in May 2017 after nearly
15 years at the National Institutes of Health working on lymphoma therapies and trials. “My goal
is to improve the cure rate for the most common
form of lymphoma, called diffuse large B-cell
lymphoma. There are lots of exciting therapies
in development, and they are really changing the
face of lymphoma,” he says.
Because all cancer tumors have proteins on
their surface, Bollard’s lab “trains” the T-cells by
loading “trainer cells,” called antigen-presenting
cells, with pieces of the proteins (peptides) that are
expressed by the tumor cell. Then the researchers
mix these peptide-loaded training cells with T-cells
from the patient or a healthy donor. The T-cells are
stimulated by the tumor peptides to reproduce in
the laboratory, growing to large enough numbers
that they can then be infused back into the patient.
“These [enhanced] T-cells,” explains Bollard, “will
then kill the tumor target, get stimulated, and continue to replicate in the patient.
“In some ways it’s like a cancer vaccine,” she
explains, “but you’re doing the job of the vaccines
in the lab.”
Adult trials began in the fall of 2016, and pediatric
patients joined the study in April 2017. “We started
with patients who’d had a bone marrow transplant,”
says Bollard. “What we want to do with Kieron is to
incorporate patients who are ineligible for transplants, or who weren’t going to have a transplant,
and combine [TAA-T] with other immunotherapies
— for instance, adding checkpoint inhibitors.”
Checkpoint inhibitors are molecules that
block immune checkpoints, which are receptors
or ligands that modulate the immune response.
In many cancers, tumor cells express these checkpoints to “put the brakes on” the immune system.
Blocking the immune checkpoint thus releases
the brakes.
“Tumors are clever,” Bollard says with a wry
grin, “and they try to resist attack from the immune system. We’ve always treated cancer with
different drugs. My feeling now is we should treat
cancer with different immune therapies. And as
long as you don’t increase toxicity to crazy levels, it’s really enhancing the immune therapy to
increase efficacy.”

Arming the Immune System
Humans’ immune system features
a variety of white blood cells — including macrophages, dendritic cells, and
several types of lymphocytes — each
with a different method for protecting
the body from foreign invasion or disease. These types of white blood cells
circulate to every part of the body,
providing protection from cancer and
other diseases.
>> Macrophages are white blood cells
that swallow and digest foreign
particles and signal other immune
system cells to go into action.
>> Dendritic cells present the foreign
cells to the immune system.
>> Lymphocytes include B-cells, T-cells,
and natural killer cells (NK) cells:
>> B-cells make antibodies that
tag foreign or abnormal cells
so other parts of the immune
system can destroy them.
>> T-cells directly attack cancer
cells and signal other immune
system cells to defend the body.
>> NK cells find, bind to, and kill
foreign invaders or damaged
cells in the body.

Bollard opens her computer and pulls up a
graphic that displays the huge number of immunotherapy projects going on around the world.
It’s nearly as vast and dense as a chart of stars. For
years, she explains, oncologists have thought of
cancer as a disease that needed to be treated by
drugs. “Those of us who were proponents of the
immune system being our best defense against
cancer were looked at with a pretty dim view,”
she says.
“Whether or not these cells are the be-all and
end-all, what this means is that the community is
now understanding that the immune system is really our first line of defense against cancer,” says
Bollard. “We should be harnessing it early in the
disease process and not waiting until we’ve killed
off the immune system with multiple lines of chemotherapy and/or radiation, and then trying to
get the immune system to help us.”

The George Washington University Cancer Center
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BY STEVE GOLDSTEIN

Gazing at the iconic 19th-century Japanese woodcut known as “The Great Wave
off Kanagawa,” one would hardly suspect it contains a key to a medical breakthrough.
Yet the pigment in the artwork has opened a new perspective in the treatment of juvenile cancer.
The artist, Hokusai, used Prussian blue pigment
in his masterpiece. By combining the same deep
blue nanoparticles with an immunotherapy class
called checkpoint inhibitors, researchers have
engineered a “nanoimmunotherapy” for treating
neuroblastoma, a leading cause of cancer-related
death among children. The nanoparticles are administered to neuroblastoma tumors, where they
are activated with near infrared light. The light activation causes the nanoparticles to heat and destroy tumor tissue and elicit a robust anti-tumor response from the immune system. These anti-tumor
effects are made more potent by the administration of the checkpoint inhibitor treatment.
Nanoimmunology, as the field is called, is really the synthesis of nanotechnology and immunotherapy — a marriage of engineering and medicine.
THE SYNTHESIS OF NANOTECHNOLOGY
Nano is the science of tiny, explains Rohan FerAND IMMUNOTHERAPY
Rohan Fernandes, PhD, is the leader
nandes, PhD, the leader of a team in the George
of a team in the George Washington
Washington University (GW) Cancer Center, inteUniversity Cancer Center integrating
grating nanoscience with the immune response.
nanoscience with the immune response.
“Nanoimmunology takes these tiny particles that
can interact with the immune system to elicit a robust response for any therapeutic purpose, whether it be infections or cancer,” says
Fernandes, who also serves as assistant professor of medicine at the GW School of
Medicine and Health Sciences (SMHS).
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“We try to break up the tumor
so that the tumor cells are killed
by the nanoparticles, and in
doing so we present the dying
tumor cells to the immune
system. Simultaneously,
we take the brakes off the
immune system, which
recognizes the tumor cells,
so the immune system can
go after what we want.”
ROHAN FERNANDES, PhD
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How small are nanoparticles? The particles are
measured in nanometers,
a measure equal to a billionth of a meter. Nanotechnology is concerned
with the use and control
of structures that range
from one to 100 nanometers in size.
Fernandes, 39, is an
engineer by training who
earned his PhD in bioengineering from the University of Maryland. After a fellowship at Johns
Hopkins University, he came under the mentorship
AN ENGINEER BY TRAINING
of Catherine Bollard, MD, associate center director
Rohan Fernandes, PhD is an engineer
for translational research and innovation at the GW
by training. He earned his PhD in
bioengineering from the University of
Cancer Center, and professor of pediatrics and of
Maryland. After a fellowship at Johns
microbiology, immunology, and tropical medicine
Hopkins University, came under the
at SMHS. Fernandes joined the GW Cancer Cenmentorship of Catherine Bollard,
ter in December 2017. “I thought my field [of nanoMD, associate center director for
technology] would be useful for immunology,” says
translational research and innovation
Fernandes, adding that the science “is actually the
at GW Cancer Center, and professor
dynamic interplay between the nano world and the
of pediatrics and of microbiology,
immunotherapy world.”
immunology, and tropical medicine
Over his career, Fernandes saw a lot of neuroblasat SMHS. Fernandes joined the GW
tomas. As a grad student, he’d become familiar with
Cancer Center in December 2017.
the story of Alexandra “Alex” Scott, who, after being
diagnosed with neuroblastoma, set up a front-yard lemonade stand to raise money for
research. A year after Alex died in 2004, her parents started the Alex’s Lemonade Stand
Foundation. “Alex’s courageous struggle was one of the motivations to undertake research that is more translational,” he explains. In January 2018, Fernandes and his team
received more than $700,000 from the foundation for neuroblastoma research.
What are checkpoint inhibitors? They are molecules that block immune checkpoints,
which are receptors or ligands that modulate the immune response. In many cancers,
tumor cells express these checkpoints to “hide” from the immune system. Blocking the
immune checkpoint “releases the brakes” on the immune system.
“We try to break up the tumor so that the tumor cells are killed by the nanoparticles,
and in doing so we present the dying tumor cells to the immune system,” Fernandes
explains. “Simultaneously, we take the brakes off the immune system, which recognizes
the tumor cells, so the immune system can go after what we want.”
Nanoparticles are made of metallic polymers that absorb the near infrared light and
dissipate the resulting energy into heat through a process known as photothermal conversion. This process helps limit the effect on healthy cells. “We get the majority of the
tumor, but there will be collateral damage to some surrounding tissue,” says Fernandes.
In a newly published paper by the team led by Fernandes, researchers describe a

technique that uses temperature control to turn immunotherapy on or off in a tumor
environment.
“When temperatures are at 60 degrees, the tumors are not immunogenic, meaning
that the immune response cannot recognize the nanoparticles,” reports Juliana CaroMejia, a University of Maryland bioengineering PhD candidate. “With the heat varying
in a window of 60 to 65 degrees, the tumor cells are expressing immunogenic markers.
Finding this window was very exciting!”
The process has already been tested on mice. The results to date indicate that treatment can boost long-term survival rates by 50 percent in the treated animals. Testing
on humans is not imminent, however. “The Food and Drug Administration is very stringent about allowing pediatric trials,” says Fernandes. His goal is to get into clinical trials
within the decade.

Nanotechnology is concerned
with the use and control of
structures that range from one
to 100 nanometers in size.

At the Core
The George Washington University (GW) Cancer Center offers its investigators a
wealth of state-of-the-art infrastructure for research and development, with additional resources available through a partnership with the Clinical and Translational Science Institute at Children’s National (CTSI-CN). Much of the infrastructure to support GW research
is organized in scientific cores offering a range of services, including the Nanofabrication
and Imaging Center, the Research Pathology Laboratory, the Flow Cytometry Core Facility, the GW Biorepository, the Biostatistics Center, and the Cancer Informatics Core.
The Nanofabrication and Imaging Center includes a class 100 cleanroom equipped
with a full spectrum of nanotechnology equipment, in addition to a microimaging suite
with ultra-high-resolution lithography and scanning electron microscopy allowing visualization of structures at the atomic level.
A Research Pathology Core provides research services for both human and animal
tissues, including tissue processing, embedding, sectioning, routine and specialized
sample staining, frozen sections, and immunohistochemistry.
The Flow Cytometry Core Facility provides sophisticated cell sorting and cell analysis experiments, as well as services in data analysis, instrument training and cytometry
education, and cytometry data.
The GW Biorepository is a comprehensive, state-of-the-art resource that features
more than 100,000 biospecimens and clinical data related to HIV malignancies, neurology, and cancer cases.
The Biostatistics Center serves as the coordinating center for large scale, multi-center
clinical trials and epidemiologic studies, offering statistical leadership for the design,
execution, and analysis of multi-center clinical trials and epidemiologic investigations.
GW Cancer Center researchers also have access to GW’s Cancer Informatics Core
pilot project, which provides collaborative informatics support for cancer research
through guidance for software use and by acting as liaison for various next-generation
sequencing data services.
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SUPPORT GROUPS
The George Washington University Cancer Center, with support provided by the Dr. Cyrus and Myrtle
Katzen Cancer Research Center (Katzen Center), offers a wide variety of holistic and wellness services
for cancer patients and their families. These groups are free of charge and open to the community.

THE GW MEDICAL
FACULTY ASSOCIATES
(GW MFA)
2150 Pennsylvania Ave., NW
Washington, D.C. 20037

ACTIVE TREATMENT
(all cancers)
Open to patients currently in treatment.
Registration required.
Second and fourth Wednesday
of each month, 12:30–1:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
ADVANCED BREAST
CANCER GROUP
Open to patients with stage IV
breast cancer. Registration required.
Fourth Tuesday of each month,
Noon–1 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
BRAIN TUMOR SUPPORT GROUP
Open to brain tumor patients and
survivors and caregivers.
Registration required.
First Tuesday of each month,
6–7:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Alicia Gray, LGSW
algray@mfa.gwu.edu
202-677-6597
CAREGIVERS’ SUPPORT GROUP
Open to caregivers of those diagnosed
with cancer to share common concerns,
give and receive advice, and learn
coping skills. Registration required.
Third Tuesday of each month,
12:30–1:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Alicia Gray, LGSW
algray@mfa.gwu.edu
202-677-6597
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GENTLE YOGA
This group introduces patients
and caregivers to the physical and
emotional benefits of yoga.
Tuesdays, 4–5 p.m.
GW Marvin Center,
Fifth floor activities room
800 21st St., NW
Facilitator: Yael Flusberg
eruiz@mfa.gwu.edu
202-677-6228
HEAD AND NECK CANCER GROUP
For head and neck cancer patients
and survivors, and their caregivers.
Registration required.
First Tuesday of each month,
12:30–1:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Alicia Gray, LGSW
algray@mfa.gwu.edu
202-677-6597
KIDS’ CLUB
For families with kids (ages 6–12)
in which a parent or sibling is in
treatment or is a survivor.
Fourth Wednesday of each month,
6–7:30 p.m.
Smith Center for Healing and the Arts
1632 U St., NW
Facilitators: Erin Price and
Lauren Broschak, LGSW
202-483-8600
MULTIPLE MYELOMA GROUP
This group is open to multiple myeloma
patients and survivors, and their
caregivers. Registration required.
Third Tuesday of each month,
5:30–6:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Alicia Gray, LGSW
algray@mfa.gwu.edu
202-677-6597
NUTRITION CLUB
First Monday of each month, Noon–1 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Jennifer Leon

202-741-6489
PROSTATE CANCER
EDUCATIONAL GROUP
The prostate cancer educational group
is open to patients and survivors, and
their caregivers. Registration required.
Second Tuesday of each month,
6–7 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
SURVIVORSHIP SERIES
An educational series featuring a
different speaker each month.
Second Thursday of each month,
11:45 a.m.–12:45 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Alicia Gray, LGSW
algray@mfa.gwu.edu
202-677-6597
YOUNG ADULT GROUP
Young adults (19– 39 years of age)
who are currently in treatment or
are cancer survivors.
Third Sunday of each month,
5–6:30 p.m.
Smith Center for Healing and the Arts
1632 U St., NW
Facilitator: Jennifer Bires
202-483-8600
Parking is validated for all groups
at the GW Cancer Center. For
more information about upcoming
support groups and events, visit

cancercenter.gwu.edu/for-patients/
patientcaregiver-support.

Executive
Committee
Jeffrey S. Akman, MD ’81, RESD
’85, vice president for health affairs,
Walter A. Bloedorn Professor of
Administrative Medicine, and
dean, the George Washington
University (GW) School of
Medicine and Health Sciences
Kimberly Russo, MBA,
MS, CEO and managing
director of GW Hospital
Robert E. Kelly, MD, CEO of
the clinical enterprise, GW
Medical Faculty Associates

External
Advisory Board
Edward Benz, MD, former
director, Dana Farber Cancer
Institute / Harvard University
William Dalton, MD, PhD, former
director, H. Lee Moffitt Cancer Center
Robert DiPaola, MD, dean,
University of Kentucky
College of Medicine
Stan Gerson, MD, director, Case
Comprehensive Cancer Center /
Case Western Reserve University
Stephen B. Gruber, MD, PhD,
MPH, director of the University
of Southern California Norris
Comprehensive Cancer Center
Helen Heslop, MD, PhD,
director, Center for Cell and Gene
Therapy, Baylor University
Marcy Waldinger, MS, former
chief administrative officer,
University of Michigan

A TEAM Approach
to Cancer Care
Representatives from 24 multidisciplinary health care teams nationwide joined the George Washington
University (GW) Cancer Center for its
inaugural TEAM (Together, Equitable,
Accessible, Meaningful) Training
program intended to help health care
organizations implement quality improvements in patient-provider communication, cultural sensitivity, health
literacy, and shared decision-making.
Leading experts discussed ways to
support health equity, patient engagement, and culturally affirming cancer
care. Keynote speaker Camara Jones,

MD, MPH, PhD, past president of the
American Public Health Association
and senior fellow at the Satcher Health
Leadership Institute, Morehouse School
of Medicine, discussed the impact
that social determinants of health and
health equity can have on patient outcomes. Fellow speaker Tamika Felder,
founder of Cervivor, a nonprofit cervical
cancer awareness and support organization, stressed the need to support
patient engagement in clinical care.
“When we were awarded funding
from the Pfizer Foundation in 2016 to
develop a project focused on reducing cancer disparities, we conducted
extensive formative research with patients and providers to find out where
the gaps [were] when it comes to
patient-provider communication,” said
Mandi Pratt-Chapman, MA, associate
center director for patient-centered
initiatives and health equity at the GW
Cancer Center. “This training is the
culmination of many months of learning for these teams, and we’re hopeful
that the insights they gain will result in
real positive changes as they return to
their home institutions.”
Before arriving, participants
completed an online course covering
topics such as engaging patients and
their loved ones in shared decisionmaking, increasing minority patient
representation in cancer research,
supporting patient self-advocacy, and
enacting culture change to support
the provision of culturally affirming
care. The TEAM training is part of a
multiphase project that includes development of patient resources.
“The GW Cancer Center is committed to advancing the health of all
patients,” said Eduardo M. Sotomayor,
MD, director of the GW Cancer Center. “Programs like TEAM represent a
significant opportunity for institutions
across the country to address inequities in health care that continue to
challenge racial, ethnic, sexual, and
gender minority cancer patients.”
To learn more, visit bit.ly/
AboutTEAMProject.
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